# Marty Makary out as FDA commissioner?

Before Jan 2027

Updated: May 8, 2026

Category: Politics

HTML: /markets/politics/marty-makary-out-as-fda-commissioner/

## Short Answer

**The model assigns meaningfully lower odds than the market for Marty Makary being out as FDA commissioner Before Jan 1, 2027, with the model at 67.4% vs the market at 82.0%.** This outcome is likely driven by reports of significant friction and internal turmoil.

## Key Claims (January 2026)

**- - Makary reportedly faces significant friction with the White House.** - President Trump reportedly scolded Makary amidst internal turmoil.
- Controversial FDA decisions on mifepristone or e-cigarettes may trigger removal.
- HHS Secretary RFK Jr. voiced concerns about Makary's FDA leadership.
- Marty Makary was confirmed as FDA Commissioner on March 25, 2025.
- FDA Commissioners typically lack fixed term lengths for their service.

### Why This Matters (GEO)

- AI agents extract claims, not arguments.
- Improves citation probability in summaries and answer cards.
- Enables fact stitching across multiple sources.

## Executive Verdict

**Key takeaway.** **Market** at 53c is 16.2pp above the **36.8%** **model**, citing Makary's reported White House friction.

### Who Wins and Why

| Outcome | Market | Model | Why |
| --- | --- | --- | --- |
| Before Jun 1, 2026 | 53.0% | 36.8% | The Commissioner is reportedly on 'thin ice' with the White House due to friction and internal turmoil. |
| Before Jul 1, 2026 | 57.0% | 38.5% | The Commissioner is reportedly on 'thin ice' with the White House due to friction and internal turmoil. |
| Before Aug 1, 2026 | 72.0% | 54.2% | The Commissioner is reportedly on 'thin ice' with the White House due to friction and internal turmoil. |

## Model vs Market

| Outcome | Market Probability | Octagon Model Probability |
| --- | --- | --- |
| Before Jun 1, 2026 | 53.0% | 36.8% |
| Before Jul 1, 2026 | 57.0% | 38.5% |
| Before Aug 1, 2026 | 72.0% | 54.2% |
| Before Jan 1, 2027 | 82.0% | 67.4% |

- Expiration: January 1, 2027

## Market Behavior & Price Dynamics

This prediction market has experienced a significant and rapid upward trend. The probability of Marty Makary leaving his role as FDA Commissioner before January 2027 has climbed from a low of 16.0% on May 05, 2026, to its current price of 53.0%. The most dramatic movement was a 26 percentage point spike on May 06, which appears to be directly caused by traditional news reports detailing mounting pressure on Makary from the White House and the pharmaceutical industry. This was followed by another 11 percentage point spike on May 08, pushing the price over the 50% threshold. The provided context does not offer a specific catalyst for this second jump.

The overall trading volume of 10,421 contracts indicates substantial market participation and conviction. The price action suggests a major shift in market sentiment over a very short period. After the initial surge, the market established a new trading range, with the 42-46% zone potentially acting as a new support level and the current price of 53.0% serving as a recent high. The chart suggests the market is highly reactive to news concerning Makary's standing within the administration. The current price indicates that traders, on aggregate, now believe it is more likely than not that Makary will depart from his position before the market's resolution date.

## Significant Price Movements

#### 📈 May 08, 2026: 11.0pp spike

Price increased from 42.0% to 53.0%

**Outcome:** Before Jun 1, 2026

**What happened:** The provided web research does not contain any information regarding social media activity, traditional news, or market structure factors on or around May 08, 2026, which is when the market price movement occurred. All available sources detail events from 2025, such as Marty Makary's confirmation as FDA Commissioner in March 2025 [[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner)[[^]](https://en.wikipedia.org/wiki/Marty_Makary)[[^]](https://www.fightcancer.org/releases/us-senate-confirms-dr-marty-makary-fda-commissioner)[[^]](https://www.fda.gov/about-fda/fda-leadership-1907-today/commissioners) and his testimony in May 2025 [[^]](https://www.aha.org/news/headline/2025-05-22-fda-commissioner-makary-testifies-fy-2026-discretionary-budget-senate-appropriations-subcommittee). Without relevant information corresponding to May 2026, it is not possible to identify the primary driver of this specific prediction market price spike. Therefore, social media's role in this particular movement cannot be determined from the given data.

#### 📈 May 06, 2026: 26.0pp spike

Price increased from 20.0% to 46.0%

**Outcome:** Before Jun 1, 2026

**What happened:** On May 06, 2026, the 26.0 percentage point spike in the prediction market was primarily driven by traditional news reports from May 2026 detailing increasing pressure on Marty Makary. These reports highlighted growing discontent among White House administration officials and the pharmaceutical industry regarding Makary's performance as FDA commissioner [[^]](https://www.biospace.com/fda/makary-defends-replimune-melanoma-rejection-again-as-fda-tensions-build)[[^]](https://www.biopharmadive.com/news/fda-after-turbulent-year-leaves-drugmakers-guessing-on-its-direction/815482/). This information, appearing to coincide with the price movement, likely fueled speculation about his imminent departure, despite a White House spokesperson stating there were "currently no plans to replace him" [[^]](https://www.biospace.com/fda/makary-defends-replimune-melanoma-rejection-again-as-fda-tensions-build). Social media was irrelevant as no specific activity was identified in the provided sources.

## Contract Snapshot

This market resolves to "Yes" if Marty Makary formally and permanently vacates his role as FDA Commissioner with an actual departure date before July 1, 2026; otherwise, it resolves to "No." The market opened on May 5, 2026, and will close early if the outcome occurs, or by June 30, 2026, at 11:59 PM EDT, if not. Special conditions include that temporary leaves do not qualify as leaving, death in the role may resolve to the last fair price, and re-occupying the role after leaving will not reverse an initial departure.

## Market Discussion

Marty Makary was sworn in as FDA Commissioner on April 1, 2025, and is currently listed in the role [[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner)[[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary). However, Notus.org reported on May 5, 2026, that Makary is on "thin ice" with the White House due to conflicts, including his blocking of flavored e-cigarettes, though no immediate ouster plans were reported [[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice)[[^]](https://nypost.com/2026/05/07/us-news/knives-out-for-fda-headmarty-makary-after-he-blocks-then-oks-vape-flavors/). The prediction market resolves Yes if Makary leaves his position before June 1, 2026 [[^]](https://kalshi.com/markets/kxmakaryout/kxmakaryout-26may).

## Market Data

| Contract | Yes Bid | Yes Ask | Last Price | Volume | Open Interest |
| --- | --- | --- | --- | --- | --- |
| Before Aug 1, 2026 | 70% | 71% | 72% | $968.55 | $781 |
| Before Jan 1, 2027 | 83% | 84% | 82% | $762 | $532 |
| Before Jul 1, 2026 | 59% | 61% | 57% | $1,797.12 | $1,432.12 |
| Before Jun 1, 2026 | 39% | 40% | 53% | $10,421.32 | $5,286.52 |

## What forthcoming FDA decisions on mifepristone or e-cigarettes could trigger Marty Makary's removal before 2027?

Makary Assumed Office | April 1, 2025 [[^]](https://www.guttmacher.org/news-release/2026/fifth-circuit-decision-directs-fda-restrict-mifepristone-access) |
SCOTUS Mifepristone Ruling Due | On or before May 11, 2026 [[^]](https://abortionfunds.org/mifepristone-telehealth-access-may-2026/) |
First Fruit-Flavored Vapes Authorized | May 5, 2026 [[^]](https://www.washingtonpost.com/health/2026/05/05/fda-approves-flavored-vapes/)[[^]](https://respiratory-therapy.com/public-health/smoking/vaping-ecigarettes/fda-approves-more-vaping-products/)[[^]](https://www.fda.gov/news-events/press-announcements/fda-expands-market-access-authorizes-new-ends-products)[[^]](https://www.pharmacytimes.com/view/fda-authorizes-first-ever-fruit-flavored-ends-products-marking-major-policy-shift) |

**Marty Makary faces potential removal amidst controversial FDA decisions by 2027**

Marty Makary faces potential removal amidst controversial FDA decisions by 2027. As the 27th Commissioner of Food and Drugs since April 1, 2025 [[^]](https://www.guttmacher.org/news-release/2026/fifth-circuit-decision-directs-fda-restrict-mifepristone-access), he could be removed before January 2027 due to upcoming FDA decisions on highly controversial topics: mifepristone and e-cigarettes [[^]](https://www.guttmacher.org/news-release/2026/fifth-circuit-decision-directs-fda-restrict-mifepristone-access)[[^]](https://www.vaporfi.com/learn/vapor-cigarette-regulation.html)[[^]](https://www.kff.org/womens-health-policy/louisiana-v-fda-access-to-mifepristone-back-at-the-supreme-court/)[[^]](https://www.healthaffairs.org/content/forefront/fda-s-liberalization-mifepristone-dispensing-securing-future-access-medical-abortion). His tenure has already involved reported friction with the White House over policy directions, particularly concerning flavored e-cigarettes [[^]](https://www.wonderwall.com/politics/president-donald-trump-fda-commissioner-marty-makary-chopping-block/)[[^]](https://www.thedailybeast.com/trump-sets-sights-on-fda-commissioner-marty-makary-in-firing-spree/)[[^]](https://tobaccoreporter.com/2026/05/05/wsj-reports-trump-pressuring-fda-to-move-on-flavored-vapes/)[[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice). Regarding mifepristone, the U.S. Supreme Court is currently reviewing a Fifth Circuit Court of Appeals decision from May 1, 2026, which temporarily reinstituted in-person dispensing rules [[^]](https://www.guttmacher.org/news-release/2026/fifth-circuit-decision-directs-fda-restrict-mifepristone-access)[[^]](https://www.kff.org/womens-health-policy/louisiana-v-fda-access-to-mifepristone-back-at-the-supreme-court/)[[^]](https://abortionfunds.org/mifepristone-telehealth-access-may-2026/)[[^]](https://dredf.org/fifth-circuit-la-v-fda/)[[^]](https://www.texastribune.org/2026/05/07/texas-abortion-pills-ban-mifepristone-explainer/). The Supreme Court temporarily halted this decision until May 11, 2026, and is expected to issue a final ruling by that date on whether mail dispensing can continue [[^]](https://abortionfunds.org/mifepristone-telehealth-access-may-2026/). The FDA is also reviewing mifepristone's safety data and its Risk Evaluation and Mitigation Strategy (REMS) program, with a status report due by October 7, 2026 [[^]](https://www.kff.org/womens-health-policy/louisiana-v-fda-access-to-mifepristone-back-at-the-supreme-court/)[[^]](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation)[[^]](https://reproductiverights.org/resources/threats-to-abortion-pill-access-united-states/). Despite acknowledging he would act if new data emerged, Makary stated in April 2025 that he had "no plans to take action" to restrict mifepristone, a position that drew criticism from some Republicans [[^]](https://www.semafor.com/article/04/24/2025/fdas-marty-makary-no-plans-to-pull-abortion-pill-mifepristone)[[^]](https://www.pbs.org/newshour/show/what-the-new-fda-commissioner-says-about-possible-restrictions-on-abortion-medication)[[^]](https://www.guttmacher.org/article/2025/06/misinformation-campaign-trying-bring-down-abortion-pills).

E-cigarette regulation, especially flavored products, is another highly scrutinized area. Makary has reportedly encountered pressure from the Trump administration on this issue [[^]](https://www.washingtonpost.com/health/2026/05/05/fda-approves-flavored-vapes/)[[^]](https://www.pharmacytimes.com/view/fda-authorizes-first-ever-fruit-flavored-ends-products-marking-major-policy-shift)[[^]](https://www.wonderwall.com/politics/president-donald-trump-fda-commissioner-marty-makary-chopping-block/)[[^]](https://www.thedailybeast.com/trump-sets-sights-on-fda-commissioner-marty-makary-in-firing-spree/)[[^]](https://tobaccoreporter.com/2026/05/05/wsj-reports-trump-pressuring-fda-to-move-on-flavored-vapes/)[[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice). A significant policy shift occurred on May 5, 2026, when the FDA authorized the first fruit-flavored vapes for adults [[^]](https://www.washingtonpost.com/health/2026/05/05/fda-approves-flavored-vapes/)[[^]](https://respiratory-therapy.com/public-health/smoking/vaping-ecigarettes/fda-approves-more-vaping-products/)[[^]](https://www.fda.gov/news-events/press-announcements/fda-expands-**market**-access-authorizes-new-ends-products)[[^]](https://www.pharmacytimes.com/view/fda-authorizes-first-ever-fruit-flavored-ends-products-marking-major-policy-shift). This decision followed reports of President Trump pressuring Makary, who some advisers initially viewed as an "obstacle" [[^]](https://www.washingtonpost.com/health/2026/05/05/fda-approves-flavored-vapes/)[[^]](https://www.pharmacytimes.com/view/fda-authorizes-first-ever-fruit-flavored-ends-products-marking-major-policy-shift)[[^]](https://www.wonderwall.com/politics/president-donald-trump-fda-commissioner-marty-makary-chopping-block/)[[^]](https://www.thedailybeast.com/trump-sets-sights-on-fda-commissioner-marty-makary-in-firing-spree/)[[^]](https://tobaccoreporter.com/2026/05/05/wsj-reports-trump-pressuring-fda-to-move-on-flavored-vapes/)[[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice). Should this authorization lead to a notable increase in youth vaping or a strong public health backlash, Makary could face accountability and calls for his removal [[^]](https://www.washingtonpost.com/health/2026/05/05/fda-approves-flavored-vapes/)[[^]](https://truthinitiative.org/press/press-release/fda-authorization-age-gated-flavored-e-cigarette-products-key-test-case). The FDA also issued draft guidance on March 11, 2026, for flavored e-cigarette premarket applications, with the public comment period ending May 11, 2026 [[^]](https://www.fda.gov/tobacco-products/ctp-newsroom/open-public-comment-period-draft-guidance-applications-flavored-e-cigarettes). In September 2025, Makary encouraged retailers to cease selling illegal flavored vapes, highlighting that many products sold are unauthorized [[^]](https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-encouraging-retailers-stop-selling-illegal-vapes).

## What specific criticisms have HHS Secretary RFK Jr. and key anti-abortion advocates leveled against Marty Makary in 2026?

Makary's FDA status | On "thin ice" with the White House due to dysfunction and friction (May 2026) [[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice) |
HHS Secretary criticism focus | Inability to effectively run FDA and address internal dysfunction [[^]](https://www.biospace.com/policy/signs-of-frustration-build-between-kennedy-makary)[[^]](https://www.reddit.com/r/DeptHHS/comments/1oxrmhv/exclusive_rfk_jr_discussed_curbing_fda_heads_role/)[[^]](https://firstwordpharma.com/story/6670690)[[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice) |
Anti-abortion criticism focus | Alleged delay of mifepristone safety review and indifference to abortion drugs [[^]](https://www.washingtonexaminer.com/policy/healthcare/3911871/anti-abortion-activist-calls-on-trump-fire-fda-marty-makary/)[[^]](https://www.pbs.org/newshour/politics/abortion-pill-rulings-bring-the-issue-back-to-the-forefront-in-a-midterm-election-year)[[^]](https://www.youtube.com/watch?v=WDZXxptO93M) |

**HHS Secretary RFK Jr**

HHS Secretary RFK Jr. voiced significant concerns about Marty Makary's FDA leadership. Discussions reportedly involved potentially limiting Makary's role and appointing a day-to-day operational lead, effectively making him a figurehead [[^]](https://www.biospace.com/policy/signs-of-frustration-build-between-kennedy-makary)[[^]](https://www.reddit.com/r/DeptHHS/comments/1oxrmhv/exclusive_rfk_jr_discussed_curbing_fda_heads_role/)[[^]](https://firstwordpharma.com/story/6670690). These considerations stemmed from reported internal dysfunction, infighting among Makary's appointed directors, and difficulties in reaching the FDA commissioner [[^]](https://www.biospace.com/policy/signs-of-frustration-build-between-kennedy-makary)[[^]](https://www.reddit.com/r/DeptHHS/comments/1oxrmhv/exclusive_rfk_jr_discussed_curbing_fda_heads_role/)[[^]](https://firstwordpharma.com/story/6670690). News reports from May 2026 indicated Makary was on "thin ice" with the White House due to "friction among staff and leadership, industry frustration and a general dysfunction in the agency" [[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice). Sources familiar with internal deliberations cited concerns about Makary's inability to effectively run the FDA, his failure to "wrangle the bureaucracy and move quickly," and not being "responsive enough" to White House and agency concerns [[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice). Despite these reported internal issues, Kennedy publicly defended Makary's record, suggesting that criticism of the FDA Commissioner stemmed from "industry anger over tougher evidentiary standards" [[^]](https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/rfk-jr-defends-makarys-us-fda-record-refutes-claims-of-chilled-biopharma-investment-TCMSTNFGKBHQ3LFNPCUXRN4EVE/).

Anti-abortion advocates heavily criticized Marty Makary for alleged mifepristone safety review delays. Key anti-abortion advocates primarily alleged that Makary deliberately delayed a comprehensive safety review of mifepristone until after the 2026 midterm elections for political reasons [[^]](https://www.washingtonexaminer.com/policy/healthcare/3911871/anti-abortion-activist-calls-on-trump-fire-fda-marty-makary/)[[^]](https://www.pbs.org/newshour/politics/abortion-pill-rulings-bring-the-issue-back-to-the-forefront-in-a-midterm-election-year). SBA Pro-Life America specifically criticized Makary for his "indifference" to abortion drugs, citing reports that he privately expressed not "thinking about" urgent safety regulations on these drugs [[^]](https://www.youtube.com/watch?v=WDZXxptO93M). This alleged stance fueled accusations that the FDA is "doing NOTHING while every day abortion drugs take the lives of children, put women & girls at serious risk, empower abusers, & trample state pro-life laws" [[^]](https://www.washingtonexaminer.com/policy/healthcare/3911871/anti-abortion-activist-calls-on-trump-fire-fda-marty-makary/). Critics further argued that Makary's actions or inaction were "severely undermining President Trump and Vice President Vance's pro-life credentials" and their position on states' rights, particularly by allowing the continuation of "Biden's Covid-era mail-order abortion drug rule" [[^]](https://www.washingtonexaminer.com/policy/healthcare/3911871/anti-abortion-activist-calls-on-trump-fire-fda-marty-makary/). Senator Josh Hawley (R-MO) accused the FDA of misleading Congress regarding the mifepristone review and urged Makary to "stop dithering [and] reinstate the mifepristone safety guardrails" [[^]](https://www.washingtonexaminer.com/policy/healthcare/3911871/anti-abortion-activist-calls-on-trump-fire-fda-marty-makary/).

## How does the public friction between Marty Makary and the White House compare to that faced by former Trump-era FDA Commissioner Scott Gottlieb?

Marty Makary FDA Commissioner | April 1, 2025 [[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner)[[^]](https://en.wikipedia.org/wiki/Marty_Makary) |
Scott Gottlieb Resignation | March 2019 [[^]](https://www.politico.com/story/2019/03/05/fda-commissioner-scott-gottlieb-to-resign-1205427)[[^]](https://www.npr.org/sections/health-shots/2019/03/05/700482545/fda-commissioner-scott-gottlieb-announces-he-will-resign)[[^]](https://www.biospace.com/article/scott-gottlieb-resigns-from-role-as-fda-commissioner) |
Marty Makary White House Friction | Scolded by Trump in May 2026 [[^]](https://www.washingtonexaminer.com/policy/healthcare/4557387/fda-chief-marty-makary-fire-multiple-directions/)[[^]](https://www.wonderwall.com/politics/president-donald-trump-fda-commissioner-marty-makary-chopping-block/) |

**Marty Makary's FDA tenure faced significant public friction with the White House**

Marty Makary's FDA tenure faced significant public friction with the White House. Makary, who was sworn in as FDA Commissioner on April 1, 2025 [[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner)[[^]](https://en.wikipedia.org/wiki/Marty_Makary), was publicly scolded by President Trump in May 2026 for slow approvals of vape products, particularly fruit flavors [[^]](https://www.washingtonexaminer.com/policy/healthcare/4557387/fda-chief-marty-makary-fire-multiple-directions/)[[^]](https://www.wonderwall.com/politics/president-donald-trump-fda-commissioner-marty-makary-chopping-block/). Following this incident, internal reports suggested Makary was on "thin ice" and the "chopping block," even though the FDA approved the vapes shortly thereafter [[^]](https://www.washingtonexaminer.com/policy/healthcare/4557387/fda-chief-marty-makary-fire-multiple-directions/)[[^]](https://www.msn.com/en-us/money/general/paranoia-turmoil-and-backlash-inside-the-fda-under-marty-makary/ar-AA22m4n6?apiversion=v2&batchservertelemetry=1&domshim=1&noservercache=1&noservertelemetry=1&renderwebcomponents=1&wcseo=1)[[^]](https://www.wonderwall.com/politics/president-donald-trump-fda-commissioner-marty-makary-chopping-block/)[[^]](https://www.nj.com/politics/2026/05/knives-out-for-trump-official-even-after-key-u-turn.html). Makary also reportedly experienced internal clashes with staff and promoted a deputy against the White House's expressed preferences [[^]](https://www.washingtonexaminer.com/policy/healthcare/4557387/fda-chief-marty-makary-fire-multiple-directions/)[[^]](https://www.msn.com/en-us/money/general/paranoia-turmoil-and-backlash-inside-the-fda-under-marty-makary/ar-AA22m4n6?apiversion=v2&batchservertelemetry=1&domshim=1&noservercache=1&noservertelemetry=1&renderwebcomponents=1&wcseo=1)[[^]](https://www.nj.com/politics/2026/05/knives-out-for-trump-official-even-after-key-u-turn.html).

In stark contrast, Scott Gottlieb maintained a notably positive relationship with the Trump administration. Gottlieb resigned as FDA Commissioner in March 2019, citing personal family reasons [[^]](https://www.politico.com/story/2019/03/05/fda-commissioner-scott-gottlieb-to-resign-1205427)[[^]](https://www.npr.org/sections/health-shots/2019/03/05/700482545/fda-commissioner-scott-gottlieb-announces-he-will-resign)[[^]](https://www.biospace.com/article/scott-gottlieb-resigns-from-role-as-fda-commissioner). His departure was met with praise from President Trump, who publicly tweeted that Gottlieb had performed an "absolutely terrific job," and the Department of Health and Human Services also commended his work [[^]](https://www.politico.com/story/2019/03/05/fda-commissioner-scott-gottlieb-to-resign-1205427)[[^]](https://www.npr.org/sections/health-shots/2019/03/05/700482545/fda-commissioner-scott-gottlieb-announces-he-will-resign)[[^]](https://www.biospace.com/article/scott-gottlieb-resigns-from-role-as-fda-commissioner). During his time as commissioner, there were no reports of Gottlieb being fired or experiencing any significant public clashes with the White House [[^]](https://www.politico.com/story/2019/03/05/fda-commissioner-scott-gottlieb-to-resign-1205427)[[^]](https://www.npr.org/sections/health-shots/2019/03/05/700482545/fda-commissioner-scott-gottlieb-announces-he-will-resign)[[^]](https://www.biospace.com/article/scott-gottlieb-resigns-from-role-as-fda-commissioner).

Gottlieb's relationship evolved, becoming critical of administration interference in later years. He continued to advise President Trump on COVID-19 matters post-resignation [[^]](https://statnews.com/2021/09/21/scott-gottlieb-trump-shadow-commissioner). However, in 2020, Gottlieb, alongside seven other former commissioners, issued broader criticism, accusing the Trump administration of interfering with the FDA's independence [[^]](https://friendsofcancerresearch.org/news/the-washington-post-seven-former-fda-commissioners-accuse-trump-administration-of-undermining-the-agency/).

## What does historical data show about the average tenure of FDA Commissioners, particularly those appointed in a president's first term?

Average Tenure (First-Term Appointments) | 4 years and 0 months (1464 days) [[^]](https://en.wikipedia.org/wiki/Commissioner_of_Food_and_Drugs) |
Current FDA Commissioner | Marty Makary [[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner)[[^]](https://en.wikipedia.org/wiki/Marty_Makary)[[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.hhs.gov/about/leadership/martin-makary.html)[[^]](https://en.wikipedia.org/wiki/Commissioner_of_Food_and_Drugs) |
Current Commissioner Assumed Office | April 1, 2025 [[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner)[[^]](https://en.wikipedia.org/wiki/Marty_Makary)[[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.hhs.gov/about/leadership/martin-makary.html)[[^]](https://en.wikipedia.org/wiki/Commissioner_of_Food_and_Drugs) |

**FDA Commissioners typically lack a fixed term length for their service**

FDA Commissioners typically lack a fixed term length for their service. Historically, Commissioners appointed during a president's first term have served an average tenure of approximately 4 years and 0 months, which totals 1464 days [[^]](https://en.wikipedia.org/wiki/Commissioner_of_Food_and_Drugs).

Marty Makary assumed office as 27th FDA Commissioner in 2025. He was confirmed as the 27th Commissioner of Food and Drugs on March 25, 2025, following his nomination by President Donald Trump. Makary officially assumed office on April 1, 2025 [[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner)[[^]](https://en.wikipedia.org/wiki/Marty_Makary)[[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.hhs.gov/about/leadership/martin-makary.html)[[^]](https://en.wikipedia.org/wiki/Commissioner_of_Food_and_Drugs). It is worth noting that appointments for this position can sometimes face delays due to controversies, which may result in periods with acting commissioners [[^]](https://en.wikipedia.org/wiki/Commissioner_of_Food_and_Drugs).

## Who were Marty Makary's key supporters during his 2025 Senate confirmation, and have they continued to publicly support him in 2026?

FDA Confirmation Date | March 25, 2025 [[^]](https://www.cbsnews.com/news/senate-confirms-marty-makary-to-lead-fda-jay-bhattacharya-to-head-nih/)[[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.ces.tech/speakers/marty-makary/)[[^]](https://www.fightcancer.org/releases/us-senate-confirms-dr-marty-makary-fda-commissioner)[[^]](https://www.hhs.gov/about/leadership/martin-makary.html)[[^]](https://www.fiercepharma.com/pharma/senate-confirms-johns-hopkins-surgeon-marty-makary-lead-fda-amid-turbulence-agency)[[^]](https://endpoints.news/senate-confirms-marty-makary-as-26th-fda-commissioner/)[[^]](https://www.washingtonexaminer.com/news/senate/3358975/senate-confirms-jay-bhattacharya-marty-makary-nih-cdc/)[[^]](https://subscriber.politicopro.com/article/2025/03/senate-moves-makary-closer-to-top-fda-job-00249109) |
Confirmation Senate Votes | All Republican Senators and Senator Dick Durbin (D-Ill.) [[^]](https://www.google.com/search?q=time+in+United+States+of+America)[[^]](https://www.cbsnews.com/news/senate-confirms-marty-makary-to-lead-fda-jay-bhattacharya-to-head-nih/)[[^]](https://oncodaily.com/voices/marty-makary-442172)[[^]](https://www.fiercepharma.com/pharma/senate-confirms-johns-hopkins-surgeon-marty-makary-lead-fda-amid-turbulence-agency)[[^]](https://endpoints.news/senate-confirms-marty-makary-as-26th-fda-commissioner/)[[^]](https://www.washingtonexaminer.com/news/senate/3358975/senate-confirms-jay-bhattacharya-marty-makary-nih-cdc/)[[^]](https://subscriber.politicopro.com/article/2025/03/senate-moves-makary-closer-to-top-fda-job-00249109)[[^]](https://ncpa.org/newsroom/qam/2025/03/27/senate-advances-health-care-nominees) |
Key Supporters in 2026 | President Donald Trump, Secretary Kennedy Jr., and the White House [[^]](https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/rfk-jr-defends-makarys-us-fda-record-refutes-claims-of-chilled-biopharma-investment-TCMSTNFGKBHQ3LFNPCUXRN4EVE/)[[^]](https://oncodaily.com/voices/fda-437755)[[^]](https://www.medpagetoday.com/special-reports/features/118739)[[^]](https://www.biospace.com/policy/signs-of-frustration-build-between-kennedy-makary)[[^]](https://www.aha.org/news/headline/2025-05-22-fda-commissioner-makary-testifies-fy-2026-discretionary-budget-senate-appropriations-subcommittee)[[^]](https://www.youtube.com/watch?v=XM7h81HrR1w)[[^]](https://www.ces.tech/speakers/marty-makary/)[[^]](https://oncodaily.com/voices/marty-makary-442172)[[^]](https://www.collins.senate.gov/newsroom/senators-collins-durbin-lead-call-urging-fda-to-strengthen-efforts-to-reduce-youth-vaping)[[^]](https://www.themainewire.com/2026/05/susan-collins-and-dick-durbin-urge-reconsideration-of-fdas-new-flavored-vape-guidance/)[[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.fightcancer.org/releases/us-senate-confirms-dr-marty-makary-fda-commissioner) |

**Marty Makary secured FDA Commissioner role with bipartisan and administrative backing**

Marty Makary secured FDA Commissioner role with bipartisan and administrative backing. Marty Makary was confirmed as the 27th Commissioner of the Food and Drug Administration (FDA) on March 25, 2025, following his nomination by President-elect Donald Trump [[^]](https://www.cbsnews.com/news/senate-confirms-marty-makary-to-lead-fda-jay-bhattacharya-to-head-nih/)[[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.ces.tech/speakers/marty-makary/)[[^]](https://www.fightcancer.org/releases/us-senate-confirms-dr-marty-makary-fda-commissioner)[[^]](https://www.hhs.gov/about/leadership/martin-makary.html)[[^]](https://www.fiercepharma.com/pharma/senate-confirms-johns-hopkins-surgeon-marty-makary-lead-fda-amid-turbulence-agency)[[^]](https://endpoints.news/senate-confirms-marty-makary-as-26th-fda-commissioner/)[[^]](https://www.washingtonexaminer.com/news/senate/3358975/senate-confirms-jay-bhattacharya-marty-makary-nih-cdc/)[[^]](https://subscriber.politicopro.com/article/2025/03/senate-moves-makary-closer-to-top-fda-job-00249109). During his 2025 Senate confirmation, he received support from all Republican Senators and Senator Dick Durbin (D-Ill.), with Durbin also voting to advance his nomination out of committee [[^]](https://www.cbsnews.com/news/senate-confirms-marty-makary-to-lead-fda-jay-bhattacharya-to-head-nih/)[[^]](https://www.fiercepharma.com/pharma/senate-confirms-johns-hopkins-surgeon-marty-makary-lead-fda-amid-turbulence-agency)[[^]](https://endpoints.news/senate-confirms-marty-makary-as-26th-fda-commissioner/)[[^]](https://www.washingtonexaminer.com/news/senate/3358975/senate-confirms-jay-bhattacharya-marty-makary-nih-cdc/)[[^]](https://subscriber.politicopro.com/article/2025/03/senate-moves-makary-closer-to-top-fda-job-00249109)[[^]](https://www.google.com/search?q=time+in+United+States+of+America)[[^]](https://oncodaily.com/voices/marty-makary-442172)[[^]](https://ncpa.org/newsroom/qam/2025/03/27/senate-advances-health-care-nominees)[[^]](https://subscriber.politicopro.com/article/2025/03/senate-panel-endorses-makary-to-lead-fda-00226757)[[^]](https://ncpa.org/newsroom/qam/2025/03/14/makary-bhattacharya-other-nominees-advance-congress). President Donald Trump praised Makary's expertise, and Secretary Kennedy Jr. welcomed him to the FDA, expressing pleasure in his leadership. Further support came from organizations including the American Cancer Society Cancer Action Network (ACS CAN) and the NCPA [[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.fightcancer.org/releases/us-senate-confirms-dr-marty-makary-fda-commissioner)[[^]](https://www.fiercepharma.com/pharma/senate-confirms-johns-hopkins-surgeon-marty-makary-lead-fda-amid-turbulence-agency)[[^]](https://www.washingtonexaminer.com/news/senate/3358975/senate-confirms-jay-bhattacharya-marty-makary-nih-cdc/)[[^]](https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/rfk-jr-defends-makarys-us-fda-record-refutes-claims-of-chilled-biopharma-investment-TCMSTNFGKBHQ3LFNPCUXRN4EVE/)[[^]](https://ncpa.org/newsroom/qam/2025/03/27/senate-advances-health-care-nominees).

Commissioner Makary maintained strong administrative and continued bipartisan engagement through 2026. Secretary Kennedy Jr. publicly defended Makary's record and commended his leadership, with a spokesperson for HHS affirming Kennedy's "full trust and **confidence**." The White House also reiterated "total **confidence**" in Commissioner Makary [[^]](https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/rfk-jr-defends-makarys-us-fda-record-refutes-claims-of-chilled-biopharma-investment-TCMSTNFGKBHQ3LFNPCUXRN4EVE/)[[^]](https://oncodaily.com/voices/fda-437755)[[^]](https://www.medpagetoday.com/special-reports/features/118739)[[^]](https://www.biospace.com/policy/signs-of-frustration-build-between-kennedy-makary). Makary continues to operate under the Trump administration, as demonstrated by his testimony before Senate committees on the FDA's fiscal year 2026 budget, indicating ongoing administrative backing for his role [[^]](https://www.ces.tech/speakers/marty-makary/)[[^]](https://oncodaily.com/voices/marty-makary-442172)[[^]](https://www.aha.org/news/headline/2025-05-22-fda-commissioner-makary-testifies-fy-2026-discretionary-budget-senate-appropriations-subcommittee)[[^]](https://www.youtube.com/watch?v=XM7h81HrR1w). Additionally, Senator Durbin, alongside Senator Susan Collins (R), engaged with Commissioner Makary in May 2026, sending a bipartisan letter urging the FDA to reconsider draft guidance on flavored e-cigarettes [[^]](https://www.collins.senate.gov/newsroom/senators-collins-durbin-lead-call-urging-fda-to-strengthen-efforts-to-reduce-youth-vaping)[[^]](https://www.themainewire.com/2026/05/susan-collins-and-dick-durbin-urge-reconsideration-of-fdas-new-flavored-vape-guidance/). The American Cancer Society Cancer Action Network's 2025 statement further implies continued functional engagement with Makary in his capacity as FDA head [[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.fightcancer.org/releases/us-senate-confirms-dr-marty-makary-fda-commissioner).

## What Could Change the Odds

**Martin A.** (Marty) Makary was confirmed as the 27th FDA Commissioner on March 25, 2025, and is still treated as in-role by the agency in the retrieved FDA profile [[^]](https://www.fda.gov/about-fda/fda-organization/martin-makary)[[^]](https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner). A recent report from 2026-05-05/06 states that Makary is on "thin ice" with the White House, and anonymous officials suggest potential movement, though there were no immediate plans for his ouster [[^]](https://www.notus.org/health-science/fda-chief-marty-makary-thin-ice)[[^]](https://www.washingtonexaminer.com/policy/healthcare/4557387/fda-chief-marty-makary-fire-multiple-directions/).

**The market for Makary's tenure indicates resolution if he leaves before Jun 1, 2026, implying that market liquidity likely clusters around events in the run-up to that cutoff [[^]](https://kalshi.com/markets/kxmakaryout/kxmakaryout-26may).** Reporting links leadership instability to FDA personnel and process turmoil, including the Prasad succession context and broader internal challenges; such successor and churn dynamics are the kinds of catalysts that typically change "will he leave by date X" probabilities [[^]](https://www.investing.com/news/stock-**market**-news/fdas-makary-expects-decision-on-prasad-successor-in-coming-weeks-4642929)[[^]](https://www.msn.com/en-us/money/general/paranoia-turmoil-and-backlash-inside-the-fda-under-marty-makary/ar-AA22m4n6?apiversion=v2&batchservertelemetry=1&domshim=1&noservercache=1&noservertelemetry=1&renderwebcomponents=1&wcseo=1)[[^]](https://www.washingtonexaminer.com/policy/healthcare/4557387/fda-chief-marty-makary-fire-multiple-directions/).

## Key Dates & Catalysts

- **Expiration:** June 08, 2026
- **Closes:** January 01, 2027

## Decision-Flipping Events

- Martin A.
- (Marty) Makary was confirmed as the 27th FDA Commissioner on March 25, 2025, and is still treated as in-role by the agency in the retrieved FDA profile [^] [^] .
- A recent report from 2026-05-05/06 states that Makary is on "thin ice" with the White House, and anonymous officials suggest potential movement, though there were no immediate plans for his ouster [^] [^] .
- The **market** for Makary's tenure indicates resolution if he leaves before Jun 1, 2026, implying that **market** liquidity likely clusters around events in the run-up to that cutoff [^] .

## Related Research Reports

- [EU has a new member before 2030?](/markets/politics/international/eu-has-a-new-member-before-2030/)
- [Will Trump's birthright citizenship order come into effect?](/markets/politics/scotus-courts/will-trump-s-birthright-citizenship-order-come-into-effect/)
- [Will Trump create a $250 bill featuring himself?](/markets/politics/congress/will-trump-create-a-250-bill-featuring-himself/)
- [Which countries will normalize relations with Israel before 2027?](/markets/politics/international/which-countries-will-normalize-relations-with-israel-before-2027/)

## Historical Resolutions

No historical resolution data available for this series.

## Disclaimer

This content is for informational and educational purposes only and does not constitute financial, investment, legal, or trading advice.
Prediction markets involve risk of loss. Past performance does not guarantee future results.
We are not affiliated with Kalshi or any prediction market platform. Market data may be delayed or incomplete.

### Data Sources & Model Transparency

**Data Sources:** Octagon Deep Research aggregates information from multiple sources including news, filings, and market data.

**Freshness:** Analysis is generated periodically and may not reflect the latest developments. Verify critical information from primary sources.

## Attribution Policy

When quoting, summarizing, or reproducing Octagon AI content, attribute it to Octagon AI and link to the Octagon source URL: https://octagonai.co/markets/politics/marty-makary-out-as-fda-commissioner
If a specific page was used, cite that page rather than only the site homepage.